China Shineway Pharmaceutical (2877.HK) - Uncertainties Cloud the Outlook
264 Views22 Feb 2022 08:58
The strong performance recovery based on 2021H1 reports is a good signal, but how long the positive momentum would last is not sure because the VBP scope has expanded on TCM. So we are conservative.
SUMMARY
(Sign Up to Access)Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
- Unlock research summaries
- Follow top, independent analysts
- Receive personalised alerts
- Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.
Upgrade later to our paid plans for full-access.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 5-minute read)
Discussions
(Paid Plans Only)
Top 5%
Xinyao (Criss) Wang
HK/China Healthcare Analyst (ex-Fosun Pharma)
Price Chart(Sign Up to Access)
- China Shineway Pharmaceutical (2877HK)-Shineway Is Undervalued, but Downside Risk Is Hard to Control27 Sep 2022
- Pre-IPO Shanghai Pulse Medical Technology - The Industry, the Business and the Concerns19 Aug 2022
- Consun Pharmaceutical (1681HK)- High-Priced Acquisition & Good Performance Show Big Upside Potential16 Aug 2022
- Presentation for Webinar: China Healthcare - Outlook and Opportunities in 202217 Feb 2022
- The Concerns and Outlook About the Recent Rally in Traditional Chinese Medicine (TCM) Sector06 Jan 2022
- China Healthcare Weekly (Dec.10) - Last Monday's Plunge, New Policy of Gene Therapy, TCM Injections12 Dec 2021
x